Lineage Cell Therapeutics, Inc. (LCTX): Price and Financial Metrics

LCTX POWR Grades

• LCTX scores best on the Sentiment dimension, with a Sentiment rank ahead of 75.06% of US stocks.
• The strongest trend for LCTX is in Quality, which has been heading down over the past 26 weeks.
• LCTX's current lowest rank is in the Momentum metric (where it is better than 18.05% of US stocks).

LCTX Stock Summary

• The ratio of debt to operating expenses for LINEAGE CELL THERAPEUTICS INC is higher than it is for about just 13.95% of US stocks.
• LCTX's price/sales ratio is 24.14; that's higher than the P/S ratio of 94.92% of US stocks.
• As for revenue growth, note that LCTX's revenue has grown -37.15% over the past 12 months; that beats the revenue growth of merely 7.17% of US companies in our set.
• If you're looking for stocks that are quantitatively similar to LINEAGE CELL THERAPEUTICS INC, a group of peers worth examining would be LGVN, ONVO, FCEL, ASXC, and OMIC.
• LCTX's SEC filings can be seen here. And to visit LINEAGE CELL THERAPEUTICS INC's official web site, go to www.lineagecell.com.

LCTX Valuation Summary

• In comparison to the median Healthcare stock, LCTX's EV/EBIT ratio is 145.21% lower, now standing at -6.6.
• Over the past 243 months, LCTX's EV/EBIT ratio has gone up 39.7.

Below are key valuation metrics over time for LCTX.

LCTX Growth Metrics

The 2 year price growth rate now stands at 23.3%.
• The year over year net income to common stockholders growth rate now stands at -256.27%.
• Its 4 year net cashflow from operations growth rate is now at 23.41%.

Over the past 33 months, LCTX's revenue has gone up $10,441,000.

The table below shows LCTX's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	13.956	3.489	-48.909
2022-06-30	13.228	4.121	-50.663
2022-03-31	9.187	5.767	-48.688
2021-12-31	4.341	-23.561	-43.019
2021-09-30	3.528	-23.329	-11.995
2021-06-30	1.829	-23.328	-11.932

LCTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• LCTX has a Quality Grade of D, ranking ahead of 12.26% of graded US stocks.
• LCTX's asset turnover comes in at 0.015 -- ranking 380th of 682 Pharmaceutical Products stocks.
• INFI, ATHX, and TTNP are the stocks whose asset turnover ratios are most correlated with LCTX.

The table below shows LCTX's key quality metrics over time.